Catheter Precision Inc. stocks have been trading up by 121.76 percent following upbeat news amplifying investor optimism.
Click Here for a Millionaire's POV on Trading VTAK
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
Key Takeaways
- Two fresh patents expand Catheter Precision’s IP around cardiac arrhythmia mapping and heart-failure neuromodulation, reinforcing VTAK’s core medtech moat.
- Flyte’s direct-to-consumer jet platform has topped 1,000 users, 118 flights, and $1M in 2026 revenue, with about 170% quarter-over-quarter growth.
- A roughly 7.5% Volato stake, via about 2.9M shares, gives VTAK leverage to AI-enabled private aviation and regional air mobility.
- LifeVac safety devices will be installed across Flyte’s Cirrus Vision Jet fleet, emphasizing safety as a key differentiator.
- A marketing tie-up with GSE Worldwide and PGA TOUR golfer Emiliano Grillo targets sports professionals for Flyte’s short-haul service.
Live Update At 10:05:45 EDT: On Wednesday, July 08, 2026 Catheter Precision Inc. stock [NYSE American: VTAK] is trending up by 121.76%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Quick Financial Overview
VTAK has been trading like a classic low-priced momentum name. After days hovering under $1, Catheter Precision exploded higher on 2026/07/08, closing at $1.585 after opening at $1.21 and touching $1.64. For traders, that’s a sharp expansion in range and clear proof that headlines are finally hitting the tape.
Zooming out, VTAK closed at $0.865 on 2026/07/01 and dipped to $0.79 on 2026/07/02 before grinding back toward the $0.70–$0.80 area. The latest move is a clean breakout from that base. Intraday, the 5‑minute chart shows a premarket ramp from roughly $0.75 to above $1.10, then a surge at the open up into the mid‑$1.50s, with repeated tests of the $1.45–$1.60 band. That’s the kind of liquidity and volatility active trading thrives on.
More Breaking News
- AMPG Stock Pulls Back As Traders Watch Key Support
- NOK Stock Rides AI Partnerships And Fresh Buy Rating
- Wendy’s Stock Ignites As Meme Traders Target Short Squeeze
- LHAI Stock Draws Day Traders After Sharp Volatility Spike
Fundamentally, Catheter Precision is still a small, money‑losing company. Q1 2026 revenue was $432,000 and full trailing revenue only $819,000, while the latest quarter showed a net loss near $1.7M and free cash flow around -$2.8M. Margins are deeply negative, and the current ratio of 0.1 signals tight liquidity. But VTAK also carries a low price‑to‑sales ratio near 2.3 and price‑to‑book around 0.27, which many short‑term traders read as “story plus discount” when a catalyst hits.
Why Traders Are Watching VTAK Now
Catheter Precision is suddenly giving traders multiple storylines in one ticker. On the medtech side, VTAK just locked down two significant patents. One, in Europe, covers precise localization of cardiac arrhythmias using data from implantable devices to guide ventricular tachycardia ablation. The other, in its Cardionomix heart‑failure portfolio, targets denoising physiological signals during neuromodulation. For a microcap, that type of IP around its VIVO imaging and heart‑failure technology matters. It signals a deliberate push to defend niche territory where larger players typically look to license or partner.
At the same time, Catheter Precision’s Flyte subsidiary is turning into its own momentum story. Flyte has reported over 1,000 users, 118 flights, and more than $1M in 2026 year‑to‑date revenue, with about 170% sequential revenue growth from Q1 to Q2. That tells traders Flyte is not just a pitch deck — it’s producing real transactions, even if the base is still small.
VTAK also moved aggressively into the broader private aviation ecosystem. Through Flyte, the company acquired roughly 2.9M Volato (SOAR) shares, taking a 7.5% stake and becoming Volato’s largest shareholder as part of a financing aimed at AI‑enabled aviation and regional air mobility. Catheter Precision shares were up nearly 3% on that news, which shows the market liked the optionality.
Layer on top the LifeVac partnership — putting FDA‑authorized anti‑choking devices on every Cirrus Vision Jet — and the GSE Worldwide deal with PGA TOUR golfer Emiliano Grillo. Those give Flyte a safety‑and‑brand story built around high‑visibility customers like professional athletes. For momentum‑focused traders, VTAK is now a hybrid name: medtech IP plus an early‑stage aviation platform, both feeding the narrative behind the recent price spike.
Conclusion
For active traders, VTAK is a case study in how news flow can wake up a thinly traded stock. Catheter Precision has paired hard medtech catalysts — fresh patents around arrhythmia localization and heart‑failure neuromodulation — with a fast‑moving Flyte story built on regional air mobility, AI‑driven booking, and strategic stakes like Volato. The result is a sharp breakout from sub‑$1 levels into the mid‑$1 range, with intraday swings wide enough to reward disciplined day trading.
None of this erases the risks. Catheter Precision is burning cash, margins are deeply negative, and the balance sheet shows a current ratio of 0.1 and heavy reliance on external financing. Flyte’s revenue, while growing quickly, is still just over $1M year to date, and aviation is capital intensive. That’s why traders need to treat VTAK as a trading vehicle, not a comfort stock to marry.
The lesson is the same one Tim Sykes hammers home: “Patterns repeat, but you have to manage risk — always cut losses quickly and never believe any hot story will save you from a bad trade.” That core idea lines up with what many modern trading educators emphasize as well; as Tim Bohen, lead trainer with StocksToTrade says, “Success in trading is more about cutting losses quickly than finding winners.”. For those tracking VTAK, that means respecting both sides of the setup — the real catalysts driving volume and the real financial strain underneath. This article is for educational and research purposes only, and any trading decisions around Catheter Precision should be based on your own homework, rules, and risk tolerance.
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.